Aytu BioPharma, Inc.
Aytu BioPharma, Inc. (AYTU) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
aytu · pe ratio · data through Jun 30, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Aytu BioPharma, Inc. (AYTU) measures how much investors pay for each dollar of the company's trailing earnings. AYTU's current PE ratio of N/A is calculated by dividing its stock price of $2.29 by its TTM earnings per share of -$3.24.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-06-30
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Aytu BioPharma, Inc.You AYTU | $19M | N/A | — | -$3.24 |
 Adaptimmune Therapeutics plc ADAP | $75M | N/A | — | -$0.28 |
 Allurion Technologies Inc. ALUR | $6M | N/A | — | -$0.38 |
 Adlai Nortye Ltd. ANL | $543M | N/A | — | -$3.33 |
 Biofrontera Inc. BFRI | $12M | N/A | — | -$1.04 |
 Ekso Bionics Holdings, Inc. EKSO | $29M | N/A | — | -$4.82 |
 GeoVax Labs, Inc. GOVX | $1M | N/A | — | -$22.40 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-06-30Latest FY2025 | — | $-2.16 | — | |
2024-06-30 FY2024 | — | $-2.86 | — | |
2023-06-30 FY2023 | — | $-5.11 | — | |
2022-06-30 FY2022 | — | $-74.00 | — | |
2021-06-30 FY2021 | — | $-69.39 | — | |
2020-06-30 FY2020 | — | $-59.22 | — | |
2019-06-30 FY2019 | — | $-1210.28 | — | |
2018-06-30 FY2018 | — | $-3061.23 | — | |
2017-06-30 FY2017 | — | $-193194.38 | — | |
2016-06-30 FY2016 | — | $-1294738.36 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Aytu BioPharma, Inc. (AYTU) measures how much investors pay for each dollar of the company's trailing earnings. AYTU's current PE ratio of N/A is calculated by dividing its stock price of $2.29 by its TTM earnings per share of -$3.24.
Frequently asked questions
AYTU pe ratio · 6 questionsAYTU's current PE ratio is N/A as of 2026-06-09, based on a stock price of $2.29 and TTM EPS of -$3.24. Data sourced from Financial Modeling Prep via AYTU's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Aytu BioPharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09